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seizures was estimated for each month of follow-up for ST
patients using data on inter- and intra-patient variability in
seizure frequency. Seizure-days for pregabalin patients were esti-
mated by applying the seizure-rate reduction observed in clini-
cal trials to the estimated rate for ST. Health-state utilities were
estimated using data from a survey of RPE patients. Costs of
antiepileptic drugs were estimated using published US prices.
Cost-effectiveness was calculated alternatively in terms of incre-
mental cost per SF day gained and incremental cost per QALY
gained. RESULTS: Compared to ST alone, add-on therapy with
pregabalin 300mg/d was estimated to yield an average of 41.4
additional SF days and 0.027 additional QALYs over one year;
corresponding estimates for pregabalin 600mg/d were 48.6 
additional SF days and 0.030 additional QALYs. Incremental
cost (mean, 95% CI) per SF day gained was $30 ($24, $39) 
for pregabalin 300mg/d, and $25 ($21, $29) for pregabalin 
600mg/d. Corresponding estimates of the incremental cost per
QALY gained were $46,055 ($35,212, $66,992) and $40,638
($32,816, $50,616). CONCLUSION: The cost-effectiveness
ratio for pregabalin as an adjunct to ST in RPE patients falls
within accepted published thresholds and compares favorably to
those of other add-on antiepileptics.
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OBJECTIVES: To estimate the socio-economic cost and health-
related quality of life (HRQL) for adults with partial epilepsy in
Sweden during 2003. METHODS: 292 patients were randomly
selected from two tertiary centres (University hospital in Lund
and Umeå) and complete data was obtained from 175 patients.
Patients completed a 3 months prospective seizure diary, one ret-
rospective and one prospective health care resource utilization
questionnaire (3 months each). HRQL data were collected using
EQ-5D and a disease-speciﬁc instrument, QOLIE-31. In addi-
tion, data was collected by physicians/nurses by a one-year ret-
rospective patient chart review. Patients were categorized by
most common seizure (sz) type (simple partial, complex partial,
secondary generalized) and sz frequency (sz free, <1sz per
month, >1sz per month). Direct and indirect costs were esti-
mated using prevalence and bottom-up approach. Direct costs
included inpatient care, outpatient care, pharmaceuticals and
social services. Indirect costs were calculated based on the human
capital theory as loss of production due to temporary sick leave
and early retirement. RESULTS: The mean total annual cost per
patient due to partial epilepsy was approximately 100.000 SEK,
indirect costs accounting for approximately 60%. Disease spe-
ciﬁc costs varied between 50.000–170.000 SEK depending on sz
type and frequency. The mean total annual cost per patient based
on all data collected for the patient population was 250.000
SEK, indirect costs accounting for approximately 50%. The
patient population cost varied between 100.000–420.000 SEK
depending on seizure type and frequency. Patients with complex
partial seizure carried the highest cost and had the lowest HRQL.
Patients with no or occasional seizures reported higher HRQL
than patients with more than one sz per month. CONCLU-
SIONS: Partial epilepsy is a serious and expensive disease. The
socio-economic cost increases and HRQL deteriorates with high
seizure frequency increasing frequency of seizures and with fre-
quent complex partial seizures.
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OBJECTIVES: Multiple Sclerosis (MS) is an unpredictable,
chronic neurological disease with a prevalence in Canada of
0.24%. Prevalence of associated pain ranges from 10%–80%
with an average of about 50%. Pain can be musculoskeletal or
nerve related and affects patients’ quality of life. We estimated
the prevalence and the burden of pain due to MS in Canadian
MS patients from the perspective of society. METHODS: The
study protocol was approved by a central Institutional Research
Board and by participating hospitals. 297 patients were recruited
either through MS clinics or the MS Society. Resource utilization
data over the previous six months were collected by telephone
interviews with the patients for direct (drugs, physicians, hospi-
talizations) and indirect costs (time loss). Indirect costs were
based on time loss using the Canadian average industrial wage.
Costing was calculated with Ontario prices and fee schedules,
applying 2004 Canadian dollars ($CAD). Mean cost per patient
were determined (SD, range etc.). The burden was extrapolated
to the Canadian population using national demographics and
prevalence rates for MS and pain in MS. Spearman’s Rho
assessed the relationship between cost and pain severity.
RESULTS: The average age was 49 (±11) years, with 77%
females. The prevalence of pain due to MS in this study sample
was 71% (211/297). The mean total direct cost per patient for
pain in MS over a 6-month period was $2528 (SD = $5695),
with hospitalization as the highest contributor (mean = $711).
The mean total indirect cost for the same period was $669 (SD
= $875). We observed a positive trend between cost and pain
severity measured by the BS-11 scale (Rho = 0.291, p = 0.0001).
The projected six-month burden for Canada was $65,034,679.
CONCLUSIONS: Pain due to MS in Canada is associated with
substantial costs to patients and society.
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OBJECTIVE: Insomnia affects patients’ quality of life and
workplace productivity, and is a risk factor for costly acute
events and chronic diseases. Existing data on the costs of insom-
nia are sparse and outdated. Accordingly, in this study we esti-
mated current societal and employer costs of chronic primary
insomnia in the U.S. METHODS: Prevalence-based cost-of-
illness estimation techniques and data from secondary sources
were used to assess the economic burden of chronic primary
insomnia (i.e., insomnia that is not due to a medical, psychiatric,
or environmental cause) in the U.S. population. Costs included
insomnia medications, insomnia-attributable health events and
chronic conditions (i.e., depression, alcohol abuse, nicotine
dependency, drug abuse, accidental injuries), and lost productiv-
ity. The cost of each insomnia-attributable health consequence
was estimated by multiplying its total cost by its population
attributable risk, which is a function of the prevalence of chronic
